Neuroscience Trials Australia

Company snapshot

NTA (Neuroscience Trials Australia) is an Australian-owned, niche contract research organization (CRO) specializing in neuroscience clinical research and beyond. NTA supports pharmaceutical, biotechnology, cell therapy and device companies to undertake their phase I-IV clinical trials according to global regulatory standards, including the TGA, FDA and EMA. Our therapeutic areas of expertise inclu

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Neuroscience Trials Australia. Not investment advice.

• What is Neuroscience Trials Australia?

  Neuroscience Trials Australia is a pharma organization headquartered in CN. Primary therapeutic focus areas include Ischemic Stroke, Spinal Cord Injury, Stroke, Intracerebral Haemorrhage. NovaPharmaNews links 5 clinical program(s), 0 drug profile(s), and 0 patent record(s) to thi

• Is Neuroscience Trials Australia publicly traded?

  Neuroscience Trials Australia appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Neuroscience Trials Australia develop or market?

  We link 9 drug profile(s) where Neuroscience Trials Australia is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/neuroscience-trials-australia#company-drugs.

• What are the latest developments for Neuroscience Trials Australia?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Neuroscience Trials Australia focus on?

  Neuroscience Trials Australia focuses on Ischemic Stroke, Spinal Cord Injury, Stroke based on our analysis of their pipeline programs and drug development activities.